Unlike nuclear energy or the space race where government was the primary funder, AI development is almost exclusively led by the private sector. This creates a novel challenge for national security agencies trying to adopt and integrate the technology.

Despite the NIH budget more than tripling since 1998, the U.S. has not seen a proportional rise in breakthroughs, a phenomenon known as Eroom's Law. The core issue isn't the amount of money, but a lack of innovation in how science is funded and conducted, with incentives that discourage risk.

The "Genesis Mission" aims to use national labs' data and supercomputers for AI-driven science. This initiative marks a potential strategic shift away from the prevailing tech belief that breakthroughs like AGI will emerge exclusively from private corporations, reasserting a key role for government-led R&D in fundamental innovation.

The market is currently ignoring the long-term impact of deep cuts to research funding at agencies like the NIH. While effects aren't immediate, this erosion of foundational academic science—the "proving ground" for new discoveries—poses a significant downstream risk to the entire biotech and pharma innovation pipeline.

The most effective government role in innovation is to act as a catalyst for high-risk, foundational R&D (like DARPA creating the internet). Once a technology is viable, the government should step aside to allow private sector competition (like SpaceX) to drive down costs and accelerate progress.

Private capital is more efficient for defense R&D than government grants, which involve burdensome oversight. Startups thrive when the government commits to buying finished products rather than funding prototypes, allowing VCs to manage the risk and de-burdening small companies.

The White House is redirecting billions in research funds away from universities, which it argues have become too slow and bureaucratic. The new strategy favors direct funding to individual scientists and stronger industry partnerships, acknowledging that frontier innovation now often originates within tech companies, not traditional academia.

Government funders like the NIH are inherently risk-averse. The ideal model is for philanthropists to provide initial capital for high-risk, transformative studies. Once a concept is proven and "de-risked," government bodies can then fund the larger-scale, long-term research.

Beyond market cycles, the real danger of scarce capital is that it cuts funding for fundamental, non-narrative-driven science at the university level. This research, often supported by government grants, is the engine of the entire biopharmaceutical ecosystem, and its decline poses a long-term threat to innovation.